Journals / Mikrobiyoloji Bülteni / 2013 / Cilt: 47 - Sayı: 2

Increase in size of lymph nodes or occurrence of new lymphadenopathy during antituberculosis chemotherapy: Paradoxical response

Tüberküloz tedavisi sırasında lenf bezi büyümesi veya yeni lenf bezi oluşması: Paradoksal yanıt

Pages
385–387
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, it should be kept in mind that in TB endemic areas such as our country, paradoxical response can develop in HIV negative or non-immunocompromised TB patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this letter was to present four more cases of tuberculosis (TB) in whom paradoxical response developed.
📊
Key Findings & Data:These presented cases had not been mentioned in the manuscript namely “Paradoxical radiologic progression despite appropriate antituberculous therapy” published in Mikrobiyol Bul 2012; 46(2): 299-303.
💡
Conclusion & Impact:However, it should be kept in mind that in TB endemic areas such as our country, paradoxical response can develop in HIV negative or non-immunocompromised TB patients.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

The aim of this letter was to present four more cases of tuberculosis (TB) in whom paradoxical response developed. These presented cases had not been mentioned in the manuscript namely “Paradoxical radiologic progression despite appropriate antituberculous therapy” published in Mikrobiyol Bul 2012; 46(2): 299-303. Paradoxical response was identified in these patients by exclusion of clinical deterioration during antituberculosis therapy such as secondary infections, inadequate anti-tuberculosis therapy as a result of drug resistance, poor compliance, and adverse reactions due to therapy. The first case had received treatment due to right paratracheal tuberculous lymphadenitis and lung TB, and who exhibited a progression in lymphadenopathy (LAP) in the 5th month of treatment. Upon the completion of treatment to one year, the lesions regressed however, right inguinal LAP developed after 20 months of initiation of therapy. Inguinal lymph node biopsy revealed tuberculous lymphadenitis and the adenopathy regressed without treatment. The second case was a patient with right paratracheal tuberculous lymphadenitis, whose lesions regressed at 3rd months of treatment. However, progression was detected in the lesions at 6th month of treatment and the treatment was prolonged to one year. The third case is the one to whom anti-TB treatment was initiated upon the diagnosis of right cervical tuberculous lymphadenitis. A new LAP developed at the left cervical site and the biopsy taken from the lesion revealed nothing diagnostic. The treatment was prolonged to one year and then ceased in this patient. The fourth case is the one to whom anti-TB treatment was initiated upon the diagnosis of lung TB and who developed right paratracheal LAP at the 4th month of treatment. The anti-TB treatment was prolonged to six months in this patient. These cases were presented to draw attention to paradoxical response which is originally known to occur primarily in HIV positive patients. However, it should be kept in mind that in TB endemic areas such as our country, paradoxical response can develop in HIV negative or non-immunocompromised TB patients.

🔖

Cite This Article

YALÇINSOY, M., BARAN, A., BİLGİN, S., AFŞAR, B. B., ÇELENK, O., ESEN, M. A. (2013). Increase in size of lymph nodes or occurrence of new lymphadenopathy during antituberculosis chemotherapy: Paradoxical response. Mikrobiyoloji Bülteni, Cilt: 47 - Sayı: 2, 385–387. https://ajindex.com/articles/298592

References (13)

  1. Gönlügür U, Koşar Ş, Mirici A. Uygun antitüberküloz tedaviye rağmen paradoks radyolojik progresyon. Mikrobiyol Bul 2012; 46(2): 299-303
  2. Karagoz T, Altinoz H, Senol T, Kula O, Yarkin T, Yazicioglu O. Paradoxical response to antituberculous therapy. Turk Respir J 2003; 4(1): 17-20
  3. Sivrel Arısoy A, Tünger Ö, Özbakkaloğlu B, Borand H, Selçuki M. Tedavi sırasında intrakraniyal tüberkülomların paradoksal yayılımı: Olgu sunumu. İnfeksiyon Derg 2002; 16(1): 103-8
  4. Cesur S, Albayrak F, Özdemir D, Birengel S, Sözen TH. Pott hastalığı tedavisi sonrasında tüberkülom gelişen olgu. İnfeksiyon Derg 2003; 17(1): 89-91
  5. Baran A, Bilgin S, Afşar BB, Çelenk O, Yalçınsoy M, Esen Akaya M. Tedavi sırasında lenf bezi büyümesi veya yeni lenf bezi oluşması: Paradoksal yanıt? Türk Toraks Derneği 12. Yıllık Kongresi, 9-11 Nisan 2009, Antalya. Bildiri Özetleri Kitabı, s: 266
  6. Cheng VC, Yam WC, Woo PC, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003; 22(10): 597-602
  7. Breen R, Smith C, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59(8): 704-7
  8. Karmakar S, Sharma SK, Vashishtha R, et al. Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in north Indian population of HIV/AIDS patients receiving HAART. Clin Dev Immunol 2011; 2011: 239021
  9. Özcan A, Köksal D, Özkara Ş. HIV-negatif akciğer tüberkülozlu hastalarda tüberküloz tedavisi sırasında görülen paradoksik reaksiyonlar. Solunum Hastalıkları Derg 2010; 21(2): 49-51
  10. Akalın H, Kılıçturgay K, Akdiş C, Helvacı S, Mıstık R. İntrakraniyal tüberkülomların antitüberküloz tedavi sırasında paradoks olarak genişlemesi. Türk Mikrobiyol Cem Derg 1993; 23(2): 153-8
  11. Kazak E, Akalın H, Gürcüoğlu E ve ark. Bir postpartum tüberküloz olgusu ışığında immün rekonstitüsyon inflamatuar sendromu. Klimik Dergisi 2006; 19(2): 79-81
  12. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158(1): 157-61
  13. Lorent N, Sebatunzi O, Mukeshimana G, Van den Ende J, Clerinx J. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda. A prospective cohort study. PLoS One 2011; 6(5): 1956-66.